LOG IN
SIGN UP
MARKET
LUMO
LUMO
Lumos Pharma Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
7.68
-0.01
-0.13%
Closed 16:00 05/26 EDT
OPEN
7.52
PREV CLOSE
7.69
HIGH
7.78
LOW
7.52
VOLUME
3.37K
TURNOVER
21.62K
52 WEEK HIGH
12.05
52 WEEK LOW
6.15
MARKET CAP
64.28M
P/E (TTM)
-2.2012
1D
5D
1M
3M
1Y
5Y
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferen...
GlobeNewswire · 05/16 20:05
Lumos Pharma: Q1 Earnings Insights
Lumos Pharma (NASDAQ:LUMO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lumos Pharma missed estimated earnings by 3.37%, reporting an EPS of $-0.92 versus an esti...
Benzinga · 05/10 22:23
Lumos Pharma Q1 EPS $(0.92) Misses $(0.89) Estimate
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.89) by 3.37 percent. This is a 11.54 percent increase over losses of $(1.04) per share from the
Benzinga · 05/10 20:32
-- Earnings Flash (LUMO) LUMOS PHARMA Reports Q1 Revenue $111,000
MT Newswires · 05/10 16:06
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
Lumos Pharma's Earnings: A Preview
Lumos Pharma (NASDAQ:LUMO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Lumos Pharma will report an earnings per share (EPS) of $-0.89.
Benzinga · 05/09 17:36
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/06 14:25
Lumos Pharma Announces A Clinical Collaboration With Massachusetts General Hospital To Evaluate Oral LUM-201 In Nonalcoholic Fatty Liver Disease In A Phase 2 Investigator-initiated Trial
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial AUSTIN, Texas, May
Benzinga · 05/05 13:10
No Data
Learn about the latest financial forecast of LUMO. Analyze the recent business situations of Lumos Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LUMO stock price target is 24.33 with a high estimate of 31.00 and a low estimate of 17.00.
Current 7.68
EPS
Actual
Estimate
-0.86-0.64-0.43-0.21
Institutional Holdings
Institutions: 102
Institutional Holdings: 5.18M
% Owned: 61.94%
Shares Outstanding: 8.37M
TypeInstitutionsShares
Increased
7
7.39K
New
5
376.65K
Decreased
9
521.46K
Sold Out
5
28.24K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.88%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Hawkins
President/Chief Operating Officer/Chief Scientific Officer
John McKew
Chief Financial Officer/Chief Accounting Officer
Lori Lawley
General Counsel
Bradley Powers
Other
David Karpf
Lead Director/Independent Director
Thomas Raffin
Independent Director
An van Es-Johansson
Independent Director
Chad Johnson
Independent Director
Kevin Lalande
Independent Director
Joseph McCracken
Independent Director
Lota Zoth
No Data
No Data
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.